分析
对医药市场、供应链、技术和法规的深入分析
分析
2026年9月6日•1 分钟阅读
Eli Lilly and Novo Nordisk vie for obesity drug market amid pricing and prescriber preferences
Surveys highlight price burden, prescriber preference and patient perception as key factors as Lilly and Novo Nordisk compete with oral GLP‑1 therapies.
分析
2026年9月6日•1 分钟阅读
Pharmacies with '365' in name rise, indicating growing 365‑day service model
The share of pharmacies whose names include '365' has risen from 1.2% in 2021 to 2.79% in 2023, reflecting an expanding trend of year‑round operations.
分析
2026年9月6日•1 分钟阅读
Hanmi Pharmaceutical signs $2.3B exclusive license with Genentech for obesity drug candidate HM17321
Hanmi Pharma secured an exclusive license with Genentech worth up to $2.3 billion for obesity/metabolic disease candidate HM17321, following a $1.26 billion deal earlier this year.
分析
2026年9月6日•1 分钟阅读
Pharmacy franchise fees in Seoul deviate from traditional sales‑multiple formula
A 20‑pyeong pharmacy with 21 M KRW monthly sales was priced at 750 M KRW, while a 30 M KRW sales pharmacy fetched 600 M KRW, showing a shift from the usual 25‑30× sales rule.
分析
2026年9月5日•1 分钟阅读
Jeil Pharm focuses Zaqubo production as Quzetas and Oncap halted, raising supply concerns
Domestic P‑CAB drug Zaqubo climbs to second market share, while Jeil Pharm stops production of twin Jastafrazan products Quzetas and Oncap, leaving their future supply uncertain.
分析
2026年9月5日•1 分钟阅读
PharmaResearch’s Rejuran Cosmetic to Enter Singapore Sephora via Olive Young K‑Beauty Edit
PharmaResearch’s premium dermo‑cosmetic brand Rejuran Cosmetic will debut in Singapore Sephora’s online and offline stores from Sept 2 as part of Olive Young’s K‑Beauty Edit, accelerating its Southeast Asian expansion.
分析
2026年9月5日•1 分钟阅读
EasyMedicom partners with ISM Korea to launch CHSCA and CHSCM certifications in Korea
EasyMedicom and ISM Korea are introducing ISCEA‑certified CHSCA and CHSCM healthcare supply‑chain qualifications in South Korea to develop local expertise.
分析
2026年9月4日•1 分钟阅读
Jongkundang Q2 Outlook Steady on Obesity Drug Wegobi; Profit Forecast Slightly Below Consensus
Analyst Huh Hyemin of Kiwoom Securities forecasts Jongkundang's Q2 sales at 4.629 trillion KRW, up 8% YoY, but operating profit at 193 billion KRW, 13% lower, slightly below consensus.
分析
2026年9月4日•1 分钟阅读
Dongguk Pharmaceutical projects Q2 sales rise on overseas cosmetics growth
Analyst Park Jong‑dae of Hana Securities forecasts Dongguk Pharmaceutical’s Q2 sales at 260.5 billion KRW and operating profit at 26.4 billion KRW, driven by strong U.S. Amazon cosmetics sales and expanding pharmacy‑cosmetics market.
分析
2026年9月4日•1 分钟阅读
Pharma Companies Reshape Distribution Networks Amid Price‑Cut Policies
Government drug‑price cuts are pressuring pharma cost‑savings, prompting firms to shift to regional wholesale and accelerate independent sales operations, challenging traditional distributors.
分析
2026年9月4日•1 分钟阅读
Kwangdong Pharma's V‑Line Corn Silk Tea Hits 1.6 Billion Cumulative Sales on 20th Anniversary
Kwangdong Pharmaceutical celebrates the 20th anniversary of its flagship ready‑to‑drink corn silk tea, announcing cumulative sales of 1.61258 billion bottles and unveiling new packaging.
分析
2026年9月4日•1 分钟阅读
BooKwang Pharma's Regadex ranks second in South Korea's liver disease combo market within a year
Regadex, a liver disease combination drug by BooKwang Pharma, achieved the second highest prescription volume in South Korea's liver disease combo market within a year of launch.